Anti-Human MIF-Anti-Human MIF-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

产品中心

当前位置：首页 > 产品中心 > 免疫学产品 > 一抗

背景资料: MIF (or macrophage migration inhibitory factor) was the first lymphokine/cytokine to be recognized in the pregenomics era. Regardless, it is one of the least understood of all inflammatory mediators. Human MIF is a 12.5 kDa, 115 amino acid (aa) nonglycosylated polypeptide that is synthesized without a signal sequence. Secretion occurs nonclassically via an ABCA1 transporter. The initiating Met is removed, leaving Pro as the first amino acid. The molecule consists of two αhelices and six βstrands, four of which form a βsheet. The two remaining βstrands interact with other MIF molecules, creating a trimer. Structure-function studies suggest MIF is bifunctional with segregated topology. The N-and C-termini mediate enzyme activity (in theory). Phenylpyruvate tautomerase activity (enol to keto) has been demonstrated and is dependent upon Pro at position #1. Amino acids 50-65 have also been suggested to contain thiol protein oxidoreductase activity. MIF has proinflammatory cytokine activity centered around aa’s 49-65. On fibroblasts, MIF induces, IL1, IL8, and MMP expression; on macrophages, MIF stimulates NO production and TNF-α release following IFNγ activation. MIF apparently acts through CD74 and CD44, likely in some form of trimeric interaction. Human MIF is active on mouse cells. Human MIF is 90%, 94%, 95%, and 90% aa identical to mouse, bovine, porcine, and rat MIF, respectively.

保存建议: 该Anti-Human MIF的详细信息查看ReliaTech提供的产品说明书。溶解建议：Centrifuge vial prior to opening. Reconstitute the antibody with 500 µl sterile PBS and the final concentration is 200 µg/ml.

其他: ReliaTech全称为受体配体技术有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，总部位于德国不伦瑞克，是一家后基因组生物技术公司。ReliaTech主要专注于受体和配体的发现与研究。此外，ReliaTech也开发应用于血管与淋巴管生成研究的相关高品质试剂。目前ReliaTech提供近2800款产品，产品线主要包括重组蛋白(细胞因子、生长因子、可溶性受体)、抗体、ELISA试剂盒等。